FDA Clearance for Phase 2 Study of MT027

T‑MAXIMUM PHARMACEUTICAL announced that the U.S. Food and Drug Administration has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed B7‑H3‑targeted universal (allogeneic) CAR‑T cell therapy, for patients with brain metastases originating from lung cancer and breast cancer. This clearance marks the second FDA‑cleared Phase 2 program for MT027; the first was granted for a study in recurrent glioblastoma. Both programs have received Orphan Drug Designation (ODD) and Fast Track Designation (FTD) from the FDA, establishing a dual‑indication portfolio that covers primary and metastatic intracranial solid tumours.

Clinical Context and Unmet Need

Brain metastases are a significant clinical challenge, occurring in approximately 20 % of all cancer patients and rising to 20‑40 % among those with advanced solid tumours. In 2022, global cancer incidence reached nearly 20 million new cases, including about 2.5 million new lung‑cancer cases and 2.3 million new female breast‑cancer cases, the two leading primary tumours that give rise to brain metastases. Asia accounts for roughly half of the worldwide cancer burden, while the United States sees an estimated 200,000‑300,000 new diagnoses of brain metastases each year. These figures illustrate a large, non‑niche patient population with limited intracranial treatment options, especially after progression on systemic therapies.

Prior Clinical Milestones Supporting MT027

T‑MAXIMUM has built a foundation of clinical experience in intracranial solid‑tumour therapy. Data from an investigator‑initiated trial of MT026, a platform‑sibling of MT027, were published in Nature Communications (2026): among five patients with recurrent high‑grade glioma, one achieved a complete response and three achieved partial responses, yielding an objective response rate of 80 % with no treatment‑related Grade 3 or higher adverse events. Early clinical data for MT027 in refractory brain metastases from lung cancer were presented at the IASLC 2026 World Conference on Lung Cancer. Five heavily pre‑treated patients completed treatment; of the three evaluable patients, two partial responses were observed. The safety profile was favorable, with no Grade 3 or higher adverse events and no graft‑versus‑host disease reported.

Manufacturing Innovation

MT027 is manufactured using a fully non‑viral gene‑editing process, diverging from the industry‑standard lentiviral vector approach. This technology is intended to improve product safety, enhance batch‑to‑batch consistency, and reduce manufacturing costs. The process was locked prior to entering Phase 2 development, supporting scalable clinical supply.

Management Commentary

The company’s leadership emphasized that receiving FDA clearance for two consecutive Phase 2 studies demonstrates systematic progress built on sustained work in intracranial solid tumours. They pledged continued rigorous evaluation of safety and clinical value, steady advancement of product supply, and exploration of additional therapeutic possibilities for patients lacking effective options.

Forward‑Looking Statements

The release contains forward‑looking statements regarding the clinical development, potential therapeutic benefits, manufacturing advantages, and regulatory progress of MT027 and other candidates. These statements are subject to risks and uncertainties inherent in clinical development, regulatory review, and manufacturing, and actual results may differ materially. Early results from small patient cohorts may not predict outcomes in larger studies. T‑MAXIMUM assumes no obligation to update these statements except as required by law.